Delivery Order SPE2DR25D2206-SPE2DR26F9AF7
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Multaq 400 mg tablets (60-count packages) valued at $6,746.16. This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting open competition among qualified...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Multaq 400 mg tablets (60-count units) valued at $1,725.96. This firm fixed price delivery order, issued on August 14, 2025, with completion targeted for August 15, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The award was made through open competition with no set-aside designation, and performance will be fulfilled from the...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Multaq 400 mg tablets (60-count packages) valued at $2,515.53. This firm fixed-price delivery order is set to conclude on August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under an existing contract vehicle, reflecting the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $4,112.20. This firm fixed-price delivery order, awarded on September 23, 2025, with an ultimate completion date of September 24, 2025, represents a non-competitive, direct fulfillment under an existing contract vehicle. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor with no...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) under a firm fixed price contract valued at $4,103.15. The delivery order, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive procurement executed through an existing contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a $22,459.46 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Multaq 400 mg tablets (60-count units). This is a firm fixed-price contract with an ultimate completion date of August 14, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) under a firm fixed-price contract valued at $3,465.96. The order, issued on June 2, 2025, with an ultimate completion date of June 3, 2025, represents a routine pharmaceutical procurement through the DLA's medical supply chain. This non-set-aside competitive award demonstrates the contractor's ongoing role in supporting federal healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $11,985.90. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a delivery order, with an ultimate completion date of August 13, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $7,902.75 under a firm fixed-price contract. This non-set-aside delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs, with an ultimate completion date of August 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) valued at $3,359.77, with an ultimate completion date of September 11, 2025. This competitive award, issued September 10, 2025, utilizes firm fixed-price pricing with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9AF7Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order contract valued at $14,438.67 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count) on November 5, 2025, with completion expected by November 6, 2025. This is a firm fixed-price delivery order under a non-competitive set-aside arrangement, with fulfillment occurring at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical distributor for federal medical procurement, particularly serving the Defense Health Agency and military healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support mechanism. The prime IDC enables AmerisourceBergen to supply an extensive portfolio of pharmaceutical products and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The delivery order structure allows the government flexibility in ordering specific medications as needed while maintaining the firm fixed-price pricing model, demonstrating the efficiency of the pharmaceutical prime vendor approach for managing federal medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.4k | 11/5/25 |